RadNet, Inc. (NASDAQ:RDNT) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. RadNet (RDNT) Acquires Gleamer for €230 Million On March 2, 2026, RadNet, Inc. (NASDAQ:RDNT) announced the acquisition of Paris-based Gleamer SAS for up to €230 million. The acquisition positions the company’s subsidiary, DeepHealth, as the world’s largest radiology AI provider. Gleamer services 700 global contracts. It reported a 90% ARR growth rate between 2022 and 2025 and is expected to reac ...

On March 18, 2026, Chief Strategy Officer Gregory Sorensen reported the sale of 15,000 shares of RadNet (RDNT +0.57%) in multiple open-market transactions, according to a SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)15,000Shares withheld (direct)5,919Shares traded (direct)20,919Transaction value~$932,000Post-transaction shares (direct)1,223,923Post-transaction value (direct ownership)~$75.87 millionTransaction value based on SEC Form 4 weighted average purchase price ($62.12); post-tr ...

Summary of RadNet Presentation at KeyBank's Healthcare Forum Company Overview - **Company**: RadNet - **Industry**: Outpatient diagnostic imaging services - **Operations**: Over 400 centers across the U.S., primarily in 10 states - **Key Features**: Complementary digital health platform, self-developed IT platform, and AI integration [1][2] 2025 Performance and 2026 Outlook - **2025 Challenges**: Faced California wildfires and severe winter weather impacting operations [5] - **2025 Growth**: Achieved unprecedented growth in MRI volume (over 11%), CT volume (mid-single digits), and PET CT (over 14%) [6] - **Acquisitions**: Completed tuck-in acquisitions, including 13 centers in Southwest Florida and 6 centers in Indiana [7] - **Digital Health Growth**: Nearly 100% growth in digital health revenue, ending the year with $92 million [7] - **2026 Guidance**: Projected revenue growth of 17%-19% for imaging centers and close to 50% for digital health [8] Business Model and Market Position - **Symbiotic Relationship**: Digital health division is an extension of the imaging center business, aimed at improving workflow and efficiency [10][11] - **Technological Advancements**: Emphasis on AI, machine learning, and new technology to transform the industry [12] Revenue and EBITDA Growth Drivers - **Revenue Growth Factors**: - Acquisitions contributing to inorganic growth - Continued same-center performance with advanced imaging driving growth [14][15] - Pricing benefits from Medicare and commercial payer mix [15] - **EBITDA Growth**: Expected to grow faster than revenue, driven by operational efficiencies and expansion of hospital joint ventures [13] Advanced Imaging Trends - **Market Shift**: Over 200 basis point shift towards advanced imaging due to technology advancements and aging population [19] - **Capacity Improvements**: Upgraded MRI scanners and AI-powered scheduling to increase patient throughput [20][21] Hospital Joint Ventures - **JV Model Benefits**: - Hospitals seek partnerships to adapt to outpatient care trends and improve operational efficiency [23][24] - RadNet benefits from hospital relationships to capture imaging referrals [27] - **Current Status**: 36% of centers in joint ventures, with potential for growth beyond 50% [28] Digital Health Division - **Growth Projections**: Guiding for 45%-55% growth in annual recurring revenue (ARR) with a target of $140 million [35] - **Key Products**: - EBCD program with 46% patient adoption - iCAD acquisition expected to enhance digital health revenue [36][37] - Growth in AI clinical solutions for lung and thyroid health [38] Gleamer Acquisition - **Strategic Fit**: Gleamer enhances RadNet's AI capabilities, with significant ARR growth and cross-selling opportunities [40][43] - **Market Position**: Combined entity positioned as the largest radiology AI company globally [44] Capital Allocation Strategy - **Opportunistic Approach**: Focus on imaging center acquisitions and joint ventures, with a disciplined approach to capital deployment [46][47] - **Financial Position**: Anticipating over $100 million in free cash flow, maintaining liquidity for future opportunities [48] Regulatory Considerations - **Site Neutrality Impact**: Potential positive implications for RadNet, as hospitals may seek partnerships to adapt to regulatory changes [50][52] This summary encapsulates the key points discussed during the RadNet presentation, highlighting the company's performance, strategic direction, and market dynamics.

LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). There will be simultaneous and archived webcasts available at https://wsw.com/webc ...

Core Insights - The company recently hosted its first Investor Day and announced a significant acquisition to enhance its artificial intelligence offerings, indicating a strong strategic direction for future growth [1] - The company reported a remarkable performance in the previous year, with revenue increasing by over 14.8% and substantial EBITDA growth, marking one of the best quarters in its history [1] - There has been consistent margin improvement over the last several quarters compared to the previous year's performance [1] Performance Metrics - Aggregate volumes have been strong, with same-center performance showing excellent results [2] - MRI volume has reached historic highs, with double-digit growth in same-center performance over the last two quarters [2] - CT volume has been growing in the mid-single digits, while PET/CT has shown exceptional growth of over 14% in the last two quarters compared to the prior year [2]

RadNet FY Conference Summary Company Overview - **Company**: RadNet (NasdaqGM:RDNT) - **Event**: FY Conference held on March 12, 2026 Key Points Current State and Outlook - RadNet experienced a strong performance in 2025, with revenue growth of over **14.8%** and substantial EBITDA growth, marking the best quarter in the company's history [3][6] - The company anticipates revenue growth for 2026 in the range of **17%-19%** and EBITDA growth between **18% and 22%**, indicating expected margin improvement [6] Digital Health Segment - The digital health segment is projected to grow over **50%**, driven by both organic growth and acquisitions, including the recent acquisition of Gleamer [7] - RadNet is focusing on transparency in its digital health initiatives, introducing metrics like annual recurring revenue (ARR) for better tracking [8] Acquisition of Gleamer - The acquisition of Gleamer is significant as it enhances RadNet's AI capabilities in X-ray, which is crucial since X-ray accounts for about **25%** of RadNet's procedure volume [10][12] - Gleamer has shown impressive growth, with an ARR increase of over **90%** since 2022, and RadNet expects to integrate Gleamer's technologies to improve efficiency and reduce costs [13] Revenue Synergies - RadNet estimates **$7 million** in revenue synergies from cross-selling and upselling opportunities through the integration of Gleamer [15] - The company aims to reduce reliance on RadNet as a customer for its digital health segment from **45%** in 2025 to **33%** in 2026, with a target of below **20%** by the end of 2028 [17][18] Labor Efficiency and Cost Management - Labor costs have been a significant challenge, with a **4%-5%** increase in labor costs built into the 2026 guidance [24] - Technologies like TechLive and C-mode are being implemented to improve labor efficiency, with TechLive allowing remote MRI scanning to reduce exam room closures [25][26] Industry Trends - Advanced imaging is a key growth area, currently comprising about **28.6%** of procedure volume but driving over **60%** of revenue [29] - The company is well-positioned to capture more advanced imaging as technology evolves, with expectations for continued growth in this segment [30][31] Economic Environment - RadNet has not observed any significant changes in demand or procedure volume despite broader economic concerns, indicating resilience in its operations [33] - The company benefits from favorable Medicare pricing and strong rate increases from capitated and commercial payers, recognizing the value of outpatient services compared to hospital pricing [34][35] Strategic Positioning - RadNet's strong regional presence allows it to negotiate effectively with payers, as it comprises a significant part of the outpatient imaging market in its operational areas [34][36] Conclusion - RadNet is positioned for robust growth in 2026, driven by strategic acquisitions, a focus on digital health, and advancements in imaging technology, while effectively managing labor costs and maintaining strong relationships with payers.

Core Viewpoint - RadNet, Inc. is set to present at the 28th Annual Barclays Global Healthcare Conference, highlighting its position as a leader in diagnostic imaging services and digital health solutions [1]. Company Overview - RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States, based on the number of locations and annual imaging revenue [2]. - The company operates a network of outpatient imaging centers across several states, including Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey, New York, Texas, and Virginia [2]. - RadNet employs over 11,000 team members, including full-time and per diem employees, technologists, and contracted radiologists [2]. Presentation Details - The presentation will take place on Thursday, March 12, 2026, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) [1][2]. - The event will be held at the Loews Miami Beach Hotel [2]. - Simultaneous and archived webcasts of the presentation will be available online [2].

Core Insights - RadNet, Inc. (RDNT) is a healthcare company specializing in outpatient imaging services, with a focus on its Digital Health segment, DeepHealth, which provides workflow software and clinical AI for radiology operations [1] - The company is expanding through joint ventures with hospitals, establishing new centers, and making acquisitions, including the recent acquisition of Gleamer [1] Company Overview - RadNet operates in the healthcare sector, specifically in outpatient imaging services [1] - The Digital Health segment, DeepHealth, enhances radiology operations through advanced software and AI solutions [1] Growth Strategy - The company’s growth strategy includes forming joint ventures with hospitals, opening new imaging centers, and pursuing acquisitions to enhance its service offerings [1] - The acquisition of Gleamer is a recent example of RadNet's commitment to expanding its capabilities and market presence [1]

Core Viewpoint - RadNet has announced the acquisition of Gleamer, a Paris-based leader in artificial intelligence, indicating a strategic move to enhance its capabilities in digital health [2]. Group 1: Acquisition Details - The acquisition of Gleamer is positioned as a significant step for RadNet in expanding its digital health offerings [2]. - The conference call aims to provide deeper insights into the transaction and its implications for the company [2]. Group 2: Key Speakers - The presentation features key executives including Dr. Greg Sorensen, Chief Strategy Officer; Kees Wesdorp, Digital Health President and CEO; and Sham Sokka, Chief Operating Officer and Chief Technical Officer of Digital Health [3].

Summary of RadNet Gleamer Conference Call Company Overview - **Company**: RadNet - **Acquisition**: Recently announced acquisition of Gleamer, a Paris-based leader in artificial intelligence in healthcare [2][14] - **Business Focus**: RadNet is a leader in diagnostic imaging services and digital health solutions, operating over 430 imaging centers across 9 states in the U.S. [4][5] Industry Insights - **Market Size**: The AI-enabled health informatics market is projected to grow from $5.1 billion in 2024 to $7.7 billion by 2028, representing an 11% growth rate [8] - **Clinical AI Solutions**: This segment is expected to grow at a rate of 26%, significantly faster than traditional radiology informatics, which is growing at 5% [8] - **Challenges in Healthcare**: Key challenges include disconnected patient engagement, workforce shortages, inconsistent clinical outcomes, and fragmented technology systems, leading to inefficiencies estimated at $25 billion [9][10] Acquisition Details - **Gleamer's Performance**: Gleamer has shown a 90% annual recurring revenue growth over the last four years, managing over 30 million studies annually with 700+ customer contracts across 40 countries [14][15] - **FDA and CE Clearances**: Gleamer holds over 4 FDA and 6 CE clearances, expanding its portfolio from X-ray to CT, mammography, and MR [14][15] - **Strategic Fit**: The acquisition is expected to enhance RadNet's portfolio, accelerate commercial reach, and improve operational efficiency [15][16] Expected Synergies and Financial Projections - **Revenue Synergies**: Over $7 million in revenue synergies anticipated, with a timeline for realization extending to 2027 [28] - **Cost Synergies**: Identified cost synergies of over $4 million, expected to be realized quickly [28][30] - **Financial Guidance for 2026**: Combined revenue for RadNet and Gleamer projected to be between $135 million and $145 million, with an annual recurring revenue growth of 80%-90% [31] Operational Impact - **Radiologist Efficiency**: The integration of Gleamer's AI tools is expected to reduce radiologist burnout and improve productivity, particularly in high-volume X-ray operations [46][47] - **Automated Reporting**: Gleamer's technology will facilitate automated reporting, enhancing turnaround times and consistency in diagnoses [21][66] - **Market Expansion**: The acquisition allows RadNet to penetrate alternative care sites, such as urgent care centers, enhancing service offerings and reducing costs [72][74] Future Outlook - **Continued Innovation**: RadNet aims to leverage Gleamer's capabilities to drive innovation in clinical AI and expand its product offerings [51][55] - **Strategic Partnerships**: The company is open to exploring partnerships with emerging AI startups to enhance its technology stack [53][80] - **Market Positioning**: RadNet positions itself as a leader in the clinical radiology AI space, with a focus on maximizing patient benefits and operational efficiencies [55][70] Conclusion - The acquisition of Gleamer represents a significant strategic move for RadNet, enhancing its capabilities in the rapidly growing AI healthcare market and addressing critical challenges in radiology [84]